HK1254984A1 - 用於細胞重編程的方法和組合物 - Google Patents

用於細胞重編程的方法和組合物

Info

Publication number
HK1254984A1
HK1254984A1 HK18114094.6A HK18114094A HK1254984A1 HK 1254984 A1 HK1254984 A1 HK 1254984A1 HK 18114094 A HK18114094 A HK 18114094A HK 1254984 A1 HK1254984 A1 HK 1254984A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
cellular reprogramming
reprogramming
cellular
Prior art date
Application number
HK18114094.6A
Other languages
English (en)
Inventor
張康
侯睿
李�根
Original Assignee
優美佳生物技術有限公司
加利福尼亞大學董事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 優美佳生物技術有限公司, 加利福尼亞大學董事會 filed Critical 優美佳生物技術有限公司
Publication of HK1254984A1 publication Critical patent/HK1254984A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18114094.6A 2016-11-03 2018-11-05 用於細胞重編程的方法和組合物 HK1254984A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417194P 2016-11-03 2016-11-03
US201762479167P 2017-03-30 2017-03-30

Publications (1)

Publication Number Publication Date
HK1254984A1 true HK1254984A1 (zh) 2019-08-02

Family

ID=62021117

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114094.6A HK1254984A1 (zh) 2016-11-03 2018-11-05 用於細胞重編程的方法和組合物

Country Status (9)

Country Link
US (2) US20180119122A1 (zh)
EP (1) EP3534911A4 (zh)
JP (1) JP2021511776A (zh)
CN (2) CN110139654A (zh)
AU (1) AU2017355481A1 (zh)
BR (1) BR112019009116A2 (zh)
CA (1) CA3042691A1 (zh)
HK (1) HK1254984A1 (zh)
WO (1) WO2018085644A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520156A (zh) * 2017-01-29 2019-11-29 唐泽群 针对外源抗原和/或自身抗原的免疫调控方法
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
WO2020205664A1 (en) * 2019-03-29 2020-10-08 Youhealth Biotech, Limited Compositions and methods for cellular reprogramming to rescue visual function
EP3953452A4 (en) * 2019-04-11 2023-05-31 Agency for Science, Technology and Research METHOD OF ALTERING A CELL'S DIFFERENTIATION STATUS
CN112741906B (zh) * 2019-10-31 2022-07-05 华东师范大学 一种用于治疗b型血友病的产品
CN111235130B (zh) * 2019-11-15 2022-11-25 武汉大学 II类V型CRISPR蛋白CeCas12a及其在基因编辑的应用
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
CN115414499A (zh) * 2022-09-21 2022-12-02 天津大学 一种介导CRISPR系统的pH响应性金团簇纳米系统及其构建方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730821B2 (en) * 2000-03-16 2004-05-04 Deltagen, Inc. Transgenic mice containing retina-specific nuclear receptor gene disruptions
US6863796B2 (en) * 2002-07-02 2005-03-08 Taiwan Semiconductor Manufacturing Co., Ltd Method for reducing cu surface defects following cu ECP
US20100196889A1 (en) * 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2436777B1 (en) * 2009-05-26 2015-08-19 Xiamen University Method for detecting variations in nucleic acid sequences
WO2014134627A1 (en) * 2013-03-01 2014-09-04 The Schepens Eye Research Institute, Inc. Methods for modulating development and function of photoreceptors cells
ES2883131T3 (es) * 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
US20160237455A1 (en) * 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
BR112016013201B1 (pt) * 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
WO2015134812A1 (en) * 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US9938521B2 (en) * 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
WO2015148860A1 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
WO2015164378A1 (en) * 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Analysis of compounds for pain and sensory disorders
DK3289080T3 (da) * 2015-04-30 2021-11-08 Univ Columbia Genterapi til autosomalt dominante sygdomme
EP3347469A4 (en) * 2015-09-10 2019-02-27 Youhealth Biotech, Limited METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA
CN105567718B (zh) * 2016-01-22 2021-11-09 东华大学 一种同时表达多个sgRNA的载体的构建方法

Also Published As

Publication number Publication date
CN110139654A (zh) 2019-08-16
BR112019009116A2 (pt) 2019-10-15
US20220033792A1 (en) 2022-02-03
CA3042691A1 (en) 2018-05-11
EP3534911A4 (en) 2020-06-17
WO2018085644A1 (en) 2018-05-11
JP2021511776A (ja) 2021-05-13
AU2017355481A1 (en) 2019-05-23
EP3534911A1 (en) 2019-09-11
US20180119122A1 (en) 2018-05-03
CN108018314A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
IL248235B (en) Method and compositions for cellular immunotherapy
HK1253306A1 (zh) 抗ntb-a抗體及相關組合物和方法
SG10202104816QA (en) Methods and compositions for analyzing cellular components
HK1254984A1 (zh) 用於細胞重編程的方法和組合物
EP2989723A4 (en) PORTABLE DEVICE AND METHOD FOR CONTROLLING THEREOF
IL268684A (en) Preparations and methods for immuno-oncology
SG11202003790PA (en) Composition and method
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
EP3384038A4 (en) METHODS AND COMPOSITIONS FOR CELL REPROGRAMMING
IL272924A (en) Methods for preparing and using endoxifen
SG11201608761PA (en) Methods of cellular reprogramming
IL274524A (en) Preparations and methods for aquaculture
IL270719A (en) Biopharmaceutical compounds and related methods
EP3386594A4 (en) COMPOSITIONS AND METHODS FOR TREATING MEDICATION RESISTANT MULTI-MEDIUM GLIOBLASTOMA
GB201520255D0 (en) Composition and method
GB201705626D0 (en) Compositions and methods
GB201700116D0 (en) Method and composition
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods
GB201509420D0 (en) Composition and method
ZA201904187B (en) Method and composition
GB201703975D0 (en) Composition and methods
GB201513492D0 (en) Method and composition
ZA201807782B (en) Methods and compositions